Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. VEGF-C as a putative therapeutic target in cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Application of cell-free DNA for genomic tumor profiling: a feasibility study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Crystal Structures of Human C4.4A Reveal the Unique Association of Ly6/uPAR/α-neurotoxin Domain

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Susacs syndrom er en vigtig differentialdiagnose ved monosymptomatisk encefalopati hos yngre voksne.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Collagen density regulates the activity of tumor-infiltrating T cells

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

A key task in developing the field of personalized cancer therapy is the identification of novel molecular targets that enable treatment of cancers not susceptible to other means of specific therapy. The collagen receptor uPARAP/Endo180 is overexpressed by malignant cells in several non-epithelial cancers, notably including sarcomas, glioblastomas and subsets of acute myeloid leukemia. In contrast, in healthy adult individuals, expression is restricted to minor subsets of mesenchymal cells. Functionally, uPARAP/Endo180 is a rapidly recycling endocytic receptor that delivers its cargo directly into the endosomal-lysosomal system, thus opening a potential route of entry into receptor-positive cells. This combination of specific expression and endocytic function appears well suited for targeting of uPARAP/Endo180-positive cancers by antibody-drug conjugate (ADC) mediated drug delivery. Therefore, we utilized a specific monoclonal antibody against uPARAP/Endo180, raised through immunization of a uPARAP/Endo180 knock-out mouse, which reacts with both the human and the murine receptor, to construct a uPARAP-directed ADC. This antibody was coupled to the highly toxic dolastatin derivative, monomethyl auristatin E, via a cathepsin-labile valine-citrulline linker. With this ADC, we show strong and receptor-dependent cytotoxicity in vitro in uPARAP/Endo180-positive cancer cell lines of sarcoma, glioblastoma and leukemic origin. Furthermore, we demonstrate the potency of the ADC in vivo in a xenograft mouse model with human uPARAP/Endo180-positive leukemic cells, obtaining a complete cure of all tested mice following intravenous ADC treatment with no sign of adverse effects. Our study identifies uPARAP/Endo180 as a promising target for novel therapy against several highly malignant cancer types.

Original languageEnglish
JournalOncotarget
Volume8
Issue number27
Pages (from-to)44605-44624
Number of pages20
ISSN1949-2553
DOIs
Publication statusPublished - 4 Jul 2017

    Research areas

  • Journal Article

ID: 52425427